Skip to main content

Pancreatic Cancer and Low Dose Naltrexone (LDN)

Pancreatic Cancer is a rare cancer, with fewer than 200,000 new cases reported in the US each year.  It is among the most serious of all cancer diagnoses, with typically no realistic opportunity for a cure the median survival for untreated advanced pancreatic cancer is only 3 ½ months, with treatment extending that to approximately 8 months.  For all stages of pancreatic cancer combined the American Cancer Society describes the one-year survival rate as 20% with the five-year rate having improved only slightly over the past few decades, currently at 7%.

Because symptoms of pancreatic cancer do not typically manifest until late in the course of the disease after the cancer has spread typical treatment options of surgery, chemotherapy, and radiation are largely ineffective and provide only marginal increases in survival time.

In a series of exceptional case studies by Dr. Berkson, the combination of LDN and alpha lipoid acid (ALA) was shown to have dramatic effects for late-stage pancreatic cancer patients.   This combination was given to 4 patients with clinical and pathologically confirmed end-stage pancreatic cancer who either refused or were not suitable candidates for conventional treatment, with limited expected survival .  In an extraordinary response two of these patients achieved stabilization of their disease, halting any further progression for 78 and 39 months respectively at time of publication.   The third patient initially achieved substantial clinical benefits, discontinued the protocol ultimately succumbing to the disease 14 months later.  The 4th patient utilized the LDN/ALA to stabilize his disease to allow for traditional surgical resection.
Given the typical poor prognosis for pancreatic cancer and lack of effective treatment options, there is a strong clinical argument for utilizing the LDN/ALA protocol as an expanded option to treat this most aggressive of cancers


The Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous A-Lipoic Acid/Low-Dose Naltrexone Protocol

Burton M. Berkson, Daniel M. Rubin, and Arthur J. Berkson

Link to Paper

Revisiting the ALA/N (a-Lipoic Acid/LowDose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases

Burton M. Berkson, MD, MS, PhD,1,2 Daniel M. Rubin, ND, FABNO,3 and Arthur J. Berkson, MD1

Link to Paper

Written by David Yeazel, MS, MPH